Company intelligence / Profile preview

Kiwoom Asset Management

Ownership: Private
Employees: ~235
Development stage: Other

Overview

Kiwoom Asset Management is one of South Korea’s leading asset management firms, managing over $36.9 billion in assets as of 2024. It offers asset management services including public fund management, investment advisory, and discretionary investment. While not a biotech or pharma developer itself, it has launched ETFs focused on global pharmaceutical and biotech companies as well as domestic medical AI firms[1][3][6][10].

Industry: Investors

Beyond the preview

Go deeper on Kiwoom Asset Management.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Kiwoom Asset Management.

Explore the full profile